Off-Label Pharma Prosecutions Won’t Be Silenced By First Amendment Decision

By Erika Kelton Big pharma — which has paid billions of dollars to settle civil and criminal charges for “off-label” marketing of prescription drugs — welcomed a U.S. Court ...

AbbVie Declares Inaugural Dividend

By  AbbVie NORTH CHICAGO, Ill., /PRNewswire/ — The board of directors of AbbVie Inc. (ABBV), a global biopharmaceutical company, today declared the Company’s first quarterly ...

Abbott Gets Xience Xpedition Approval

By Zacks Equity Research Abbott Laboratories (ABT) recently announced that the US Food and Drug Administration (:FDA) has approved its Xience Xpedition everolimus eluting coronary ...

Discovery Labs CFO Becomes CEO

By Rich Smith Development-stage biotech Discovery Laboratories (NASDAQ: DSCO  ) announcedFriday that Chief Executive Officer and Chairman of the Board W. Thomas Amick has resigned ...

Pernix Acquires Cypress and Hawthorn

By Zacks Equity Research Pernix Therapeutics Holdings, Inc. (PTX) recently announced that it has completed the acquisition of Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals. Both ...

Forest Labs Settles BYSTOLIC Patent Lawsuit

By Dan Radovsky Forest Laboratories (NYSE: FRX  ) announced today it has agreed to settle the patent infringement lawsuit it had brought against Glenmark Generics. That litigation ...

Biotech insider trading case heats up with ex-SAC manager’s pleas

By Ryan McBride The U.S. government’s major case involving insider trading on biotech stocks continued to unfold this week, with a former portfolio manager from SAC Capital pleading ...

Pfizer snaps up ‘armed antibody’ for autoimmune ailments from biotech

By Ryan McBride Pfizer ($PFE) has quietly grabbed rights to an experimental “armed antibody” in early human testing against rheumatoid arthritis, with interest in advancing ...

UCSD biotech spinoff snags $18M A round to advance RNAi drugs

By Ryan McBride West Coast biotech vets have joined forces to solve one of the thorniest delivery issues in the industry–ushering RNA drugs into cells. Their startup, Solstice ...

Amicus jumps on upbeat data for Pompe drug

By Ryan McBride Amicus Therapeutics revealed its success in a small midstage study of its drug to enhance enzyme therapy in patients with the rare genetic disorder Pompe disease. On ...

Biogen asks FDA for approval of first drug in potential $1B franchise

By Ryan McBride Biogen Idec ($BIIB) has shipped its application to the FDA for approval of an experimental therapy for the rare bleeding disorder hemophilia B. And the long-lasting ...

KV Pharma Loses Another Battle Over Makena

By Ed Silverman KV Pharmaceutical may have emerged from bankruptcy in hopes of marketing still more of its Makena treatment for reducing the risk of premature births. But the troubled ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS